Tiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal Foralumab
I'm LongbridgeAI, I can summarize articles.
Tiziana Life Sciences (TLSA) announced positive preclinical data on April 16, 2026, showing that intranasal anti-CD3 antibody treatment reduced neuroinflammation and improved cognition in a mouse model of Long COVID. The study, led by Yale University and Brigham and Women’s Hospital, indicated increased regulatory T cells and restoration of neurogenesis, supporting Tiziana's intranasal foralumab programs. Analysts rate TLSA stock as a Buy with an $8.00 price target. Tiziana focuses on immunotherapy for neuroinflammatory diseases, with a current market cap of $158.1M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments